Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study

• Published in: BMC RESEARCH NOTES
• Main Authors: Abu Seman, Zahidah; Ahid, Fadly; Kamaluddin, Nor Rizan; Sahid, Ermi Neiza Mohd; Esa, Ezalia; Said, Siti Shahrum Muhamed; Azman, Norazlina; Mat, Wan Khairull Dhalila Wan; Abdullah, Julia; Ali, Nurul Aqilah; Khalid, Mohd Khairul Nizam Mohd; Yusoff, Yuslina Mat
• Format: Article
• Language: English
• Published: SPRINGERNATURE 2024
• Subjects: Life Sciences & Biomedicine - Other Topics; Science & Technology - Other Topics
• Online Access: https://www-webofscience-com.uitm.idm.oclc.org/wos/woscc/full-record/WOS:001205941900001

Objective Mutational analysis of BCR::ABL1 kinase domain (KD) is a crucial component of clinical decision algorithms for chronic myeloid leukemia (CML) patients with failure or warning responses to tyrosine kinase inhibitor (TKI) therapy. This study aimed to detect BCR::ABL1 KD mutations in CML patients with treatment resistance and assess the concordance between NGS (next generation sequencing) and Sanger sequencing (SS) in detecting these mutations. Results In total, 12 different BCR::ABL1 KD mutations were identified by SS in 22.6% (19/84) of patients who were resistant to TKI treatment. Interestingly, NGS analysis of the same patient group revealed an additional four different BCR::ABL1 KD mutations in 27.4% (23/84) of patients. These mutations are M244V, A344V, E355A, and E459K with variant read frequency below 15%. No mutation was detected in 18 patients with optimal response to TKI therapy. Resistance to TKIs is associated with the acquisition of additional mutations in BCR::ABL1 KD after treatment with TKIs. Additionally, the use of NGS is advised for accurately determining the mutation status of BCR::ABL1 KD, particularly in cases where the allele frequency is low, and for identifying mutations across multiple exons simultaneously. Therefore, the utilization of NGS as a diagnostic platform for this test is very promising to guide therapeutic decision-making.